Severe dermatomyositis: autoimmune diseases and their diagnostic delay
DOI:
https://doi.org/10.32818/reccmi.a9n1a12Keywords:
dermatomyositis, muscle weakness, deglutition, methylprednisolone, rituximabAbstract
A 34-year-old woman with erythematous skin lesions, generalized edema, asthenia and proximal muscle weakness, was diagnosed after medical evaluation and complementary tests of dermatomyositis with positive anti-Mi-2 antibodies. The patient required treatment with pulses of methylprednisolone, rituximab and immunoglobulins due to severe involvement of the esophageal muscles and proximal extremities. During the 142 days of admission, the patient presented numerous complications with a slow response to the installed treatment. At 6 months had recovered swallowing, however, she continued to be dependent for basic activities of daily living due to proximal muscle weakness in the extremities.
Downloads
Metrics
References
Fornaro M, Girolamo F, Cavagna L, Franceschini F, Giannini M, Amati A, et al. Severe muscle damage with myofiber necrosis and macrophage infiltrates characterize anti-Mi2 positive dermatomyositis. Rheumatology (Oxford). 2021; 60(6): 2916-2926. doi: https://doi.org/10.1093/rheumatology/keaa739 (último acceso mar. 2024). DOI: https://doi.org/10.1093/rheumatology/keaa739
Pinal-Fernandez I, Mecoli CA, Casal-Dominguez M, Pak K, Hosono Y, Huapaya J, et al. More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies. Neurology. 2019; 93(19): e1768-e1777. doi: https://doi.org/10.1212/WNL.0000000000008443 (último acceso mar. 2024). DOI: https://doi.org/10.1212/WNL.0000000000008443
Tanboon J, Inoue M, Hirakawa S, Tachimori H, Hayashi S, Noguchi S, et al. Pathologic features of anti-Mi-2 dermatomyositis. Neurology. 2021; 96(3): e448-e459. doi: https://doi.org/10.1212/WNL.0000000000011269 (último acceso mar. 2024). DOI: https://doi.org/10.1212/WNL.0000000000011269
Galimberti F, Li Y, Fernandez AP. Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancy-associated risk factors in a specific tertiary-care-centre cohort. Br J Dermatol. 2016; 174(1): 158-164. doi: https://doi.org/10.1111/bjd.14227 (último acceso mar. 2024). DOI: https://doi.org/10.1111/bjd.14227
Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol. 2007; 19(6): 523-529. doi: https://doi.org/10.1097/BOR.0b013e3282f01a8c (último acceso mar. 2024). DOI: https://doi.org/10.1097/BOR.0b013e3282f01a8c
Kim S, Lee S, Park H, Choi Y. P329 The role of autoantibodies in diagnosis of idiopathic inflammatory myopathies. Neuromuscular Disorders. 2023; 33(suppl.1): S96-S97. doi: https://doi.org/10.1016/j.nmd.2023.07.127 (último acceso mar. 2024). DOI: https://doi.org/10.1016/j.nmd.2023.07.127
McGrath ER, Doughty CT, Amato AA. Autoimmune myopathies: updates on evaluation and treatment. Neurotherapeutics. 2018; 15(4): 976-994. doi: https://doi.org/10.1007/s13311-018-00676-2 (último acceso mar. 2024). DOI: https://doi.org/10.1007/s13311-018-00676-2
Kronzer VL, Kimbrough BA, Crowson CS, Davis JM III, Holmqvist M, Ernste FC. Incidence, prevalence, and mortality of dermatomyositis: a population-based cohort study. Arthritis Care Res (Hoboken). 2023; 75(2): 348-355. doi: https://doi.org/10.1002/acr.24786 (último acceso mar. 2024). DOI: https://doi.org/10.1002/acr.24786
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Salvador Aguilar-Alba, Esperanza Sastre-Menor, Alba Quirós-Jiménez, Rafael Ángel Fernández de la Puebla-Giménez, Inmaculada Sánchez-Ramírez
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
